GAMMA Investing LLC Cuts Stock Holdings in Insmed, Inc. $INSM

GAMMA Investing LLC lowered its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 20.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 800 shares of the biopharmaceutical company’s stock after selling 209 shares during the period. GAMMA Investing LLC’s holdings in Insmed were worth $81,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Cullen Frost Bankers Inc. raised its position in shares of Insmed by 164.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 221 shares during the period. NBC Securities Inc. purchased a new position in shares of Insmed in the 1st quarter worth $49,000. Versant Capital Management Inc raised its holdings in shares of Insmed by 546.3% in the 1st quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 590 shares during the period. Signaturefd LLC raised its holdings in shares of Insmed by 60.0% in the 1st quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 325 shares during the period. Finally, Strategic Investment Solutions Inc. IL purchased a new position in shares of Insmed in the 1st quarter worth about $79,000.

Analyst Ratings Changes

A number of research firms have recently commented on INSM. Cowen restated a “buy” rating on shares of Insmed in a report on Thursday. JPMorgan Chase & Co. raised their price target on shares of Insmed from $111.00 to $135.00 and gave the company an “overweight” rating in a report on Wednesday, August 20th. Leerink Partners raised their target price on shares of Insmed from $100.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, June 10th. Guggenheim raised their target price on shares of Insmed from $125.00 to $172.00 and gave the company a “buy” rating in a research note on Monday, September 8th. Finally, The Goldman Sachs Group raised their price objective on Insmed from $114.00 to $142.00 and gave the company a “buy” rating in a research report on Wednesday, August 13th. Nineteen analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Insmed presently has an average rating of “Moderate Buy” and an average price target of $145.69.

Insiders Place Their Bets

In related news, insider Michael Alexander Smith sold 24,272 shares of Insmed stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $143.89, for a total value of $3,492,498.08. Following the completion of the sale, the insider owned 54,902 shares in the company, valued at approximately $7,899,848.78. The trade was a 30.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the business’s stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $145.45, for a total transaction of $11,129,834.00. Following the completion of the sale, the insider directly owned 36,461 shares of the company’s stock, valued at $5,303,252.45. The trade was a 67.73% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 277,332 shares of company stock valued at $33,842,327. 3.00% of the stock is owned by insiders.

Insmed Stock Up 3.7%

Shares of NASDAQ INSM opened at $152.80 on Friday. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $152.85. The firm has a market cap of $32.30 billion, a price-to-earnings ratio of -26.76 and a beta of 1.03. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. The stock’s 50-day simple moving average is $131.39 and its 200-day simple moving average is $98.41.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business had revenue of $107.42 million for the quarter, compared to analysts’ expectations of $104.06 million. During the same quarter in the prior year, the firm earned ($1.94) earnings per share. Insmed’s revenue for the quarter was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.